Formation primaquine-5, 6-orthoquinone, the putative active and toxic metabolite of primaquine via direct oxidation in human erythrocytes by Fasinu, P. S. et al.
Campbell University
CU FIND
Pharmaceutical Sciences Pharmacy & Health Sciences, College of
1-2019
Formation primaquine-5, 6-orthoquinone, the
putative active and toxic metabolite of primaquine
via direct oxidation in human erythrocytes
P. S. Fasinu
N. D. Nanayakkara
Y. H. Wang
N. D. Chaurasiya
H. B. Herath
See next page for additional authors
Follow this and additional works at: https://cufind.campbell.edu/pharmacy
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the Pharmacy & Health Sciences, College of at CU FIND. It has been accepted for inclusion in
Pharmaceutical Sciences by an authorized administrator of CU FIND. For more information, please contact long@campbell.edu.
Recommended Citation
Fasinu, P. S.; Nanayakkara, N. D.; Wang, Y. H.; Chaurasiya, N. D.; Herath, H. B.; McChesney, J. D.; Avula, B.; Khan, I.; Tekwani, B. L.;
and Walker, L. A., "Formation primaquine-5, 6-orthoquinone, the putative active and toxic metabolite of primaquine via direct
oxidation in human erythrocytes" (2019). Pharmaceutical Sciences. 1907.
https://cufind.campbell.edu/pharmacy/1907
Authors
P. S. Fasinu, N. D. Nanayakkara, Y. H. Wang, N. D. Chaurasiya, H. B. Herath, J. D. McChesney, B. Avula, I.
Khan, B. L. Tekwani, and L. A. Walker
This article is available at CU FIND: https://cufind.campbell.edu/pharmacy/1907
Fasinu et al. Malar J           (2019) 18:30  
https://doi.org/10.1186/s12936-019-2658-5
RESEARCH
Formation primaquine-5,6-orthoquinone, 
the putative active and toxic metabolite 
of primaquine via direct oxidation in human 
erythrocytes
Pius S. Fasinu1,3* , N. P. Dhammika Nanayakkara1, Yan‑Hong Wang1, Narayan D. Chaurasiya1, 
H. M. Bandara Herath1, James D. McChesney4, Bharathi Avula1, Ikhlas Khan1,2, Babu L. Tekwani1,5 
and Larry A. Walker1,2*
Abstract 
Background: The activity and haemolytic toxicity associated with primaquine has been linked to its reactive metab‑
olites. The reactive metabolites are thought to be primarily formed through the action of cytochrome  P450‑mediated 
pathways. Human erythrocytes generally are not considered a significant contributor to drug biotransformation. As 
erythrocytes are the target of primaquine toxicity, the ability of erythrocytes to mediate the formation of reactive 
oxidative primaquine metabolites in the absence of hepatic enzymes, was evaluated.
Methods: Primaquine and its enantiomers were incubated separately with human red blood cells and haemoglobin. 
Post‑incubation analysis was performed with UPLC–MS/MS to identify products of biotransformation.
Results: The major metabolite detected was identified as primaquine‑5,6‑orthoquinone, reflecting the pathway 
yielding putative active and haematotoxic metabolites of primaquine, which was formed by oxidative demethylation 
of 5‑hydroxyprimaquine. Incubation of primaquine with haemoglobin in a cell‑free system yielded similar results. It 
appears that the observed biotransformation is due to non‑enzymatic processes, perhaps due to reactive oxygen spe‑
cies (ROS) present in erythrocytes or in the haemoglobin incubates.
Conclusion: This study presents new evidence that primaquine‑5,6‑orthoquinone, the metabolite of primaquine 
reflecting the oxidative biotransformation pathway, is generated in erythrocytes, probably by non‑enzymatic means, 
and may not require transport from the liver or other tissues.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The association of primaquine (PQ) with haemolytic 
toxicity in certain individuals has been recognized since 
the introduction of the anti-malarial drug over six dec-
ades [1]. This toxicity was subsequently determined to be 
associated with a genetic deficiency in glucose-6-phos-
phate dehydrogenase (G6PD) [2]. Despite this limitation, 
PQ has remained in clinical use because of its unique 
therapeutic indications [3–5]. PQ is used for the radical 
cure of the persistent liver stages of Plasmodium vivax 
and Plasmodium ovale responsible for relapsing malaria 
[3–5], as well as a prophylactic for all forms of human 
malaria and as a gametocytocide for transmission inter-
ruption in falciparum malaria [6–8]. Despite this long 
history of clinical use, the mechanisms of biotransforma-
tion, efficacy and haemotoxicity are still not fully under-
stood [3–5].
Speculation that a metabolite rather than the par-
ent compound was responsible for haemotoxicity of the 
members of this class of compounds (8-aminoquinolines) 
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predates the introduction of PQ in 1950s. In 1942, 
Schönhöfer postulated the possibility of oxidative bio-
degradation of 8-aminoquinolines such as pamaquine, 
PQ’s closely related predecessor, to a biologically active 
quinone [9]. Subsequently, Josephson and co-workers 
detected a metabolite in droppings of chickens treated 
with pamaquine which had similar UV absorption spec-
tra, methaemoglobin activity (in chicken erythrocytes) 
and in  vitro anti-malarial activity against Plasmodium 
gallinaceum with that of synthetic pamaquine-orthoqui-
none, [8-(4-diethylamino-1-methylbutylamino)-5,6-qui-
nolinequinone] [10, 11].
The primaquine-derived orthoquinone, 8-(4-amino-
1-methylbutylamino)-5,6-quinolinequinone, derived by 
oxidation of PQ as shown in Fig.  1, is analogous to the 
pamaquine metabolite, lacking only the diethyl sub-
stituents on the terminal amine. Reactive oxygen spe-
cies (ROS) generated by redox-cycling of products in the 
pathway leading to PQ-5,6-orthoquinone, have also been 
proposed to be responsible for the biological activity of 
PQ [2]. Early in vitro studies have shown accumulation of 
hydrogen peroxide in erythrocytes when incubated with 
PQ and suggested the possible formation of a metabolite 
which can undergo redox-cycling in erythrocytes [12]. 
In  vitro haemolysis studies with PQ also have provided 
evidence for possible formation of a more active metabo-
lite in erythrocytes and suggested PQ-orthoquinone as 
the potential metabolite [13].
Several in  vitro studies have shown that 5-hydroxy-
PQ, 6-demethyl-5-hydroxy-PQ, and PQ-5,6-orthoqui-
none could form methaemoglobin in erythrocytes at 
much higher rates than the parent PQ [14–19], and the 
generation of ROS in erythrocytes by redox-cycling of 
PQ-5,6-orthoquinone and the corresponding 6-deme-
thyl-5-hydroxy-PQ—or perhaps, the 5-hroxy-PQ and its 
corresponding quinone-imeine—were suggested as the 
possible mechanism of this toxicity.
Malaria parasites are also known to be highly suscep-
tible to ROS [20] and generation of ROS has been pro-
posed as the mechanism of action of this class of drug 
as well as other anti-malarial oxidant drugs [21]. In nor-
mal erythrocytes, oxidative defence (glutathione, SOD, 
and catalase) can neutralize excess ROS preventing 
haematotoxicity. However, in G6PD-deficient erythro-
cytes, accumulation of ROS may occur due to impaired 
oxidative defences leading to haematotoxicity [22, 23]. 
Even though the pathway leading to  PQ-5,6-orthoqui-
none had been speculated to yield the active and toxic 
metabolite for a long time [2], it is only recently that it 
has been positively identified in a mammalian metabolite 
[19].
CYP 2D6 metabolism of PQ was shown to be required 
for its radical curative activity in humans [24–27]. A sub-
sequent animal study lends further support to the need 
for 2D6 metabolism by showing that PQ has very low 
causal prophylactic activity against sporozoite-induced 
Plasmodium berghei infection in CYP 2D knock-out 
(KO) mice when compared to wild type (WT) mice or 
humanized CYP 2D6 (KO/knock-in (KO/KI)) mice [28]. 
Building on this, Potter and co-workers carried out PQ 
metabolism studies using WT, KO and KO/KI mice [19]. 
They found that PQ-5,6-orthoquinone was the major 
(though short-lived) liver metabolite in WT mice, and 
that its concentration was reduced to very low levels in 
KO mice; furthermore, it was restored to about 25% 
of the WT concentration in KO/KI mice. The activity 
observed for the above-cited causal prophylactic study 
[28], was closely correlated with the concentration of 
the PQ-5,6-orthoquinone generated in the livers of the 
respective animal groups in the PQ pharmacokinetic 
(PK) study [19]. This is consistent with the observation 
that CYP 2D6 metabolism of PQ was required for its 
radical curative activity [24–26] and probably also for 
causal prophylactic activity in humans and confirmed 
PQ-5,6-orthoquinone as reflective of the putative active 
metabolite. In  vitro metabolic studies of PQ with CYP 
2D6 further confirmed the formation of PQ-5,6-ortho-
quinone as a metabolite [29].
However, in a subsequent treatment study of erythro-
cytic stages using a single dose of PQ, parasitaemia sup-
pression in WT mice was not statistically different from 
that in CYP 2D KO mice, showing that the genetic dele-
tion of the CYP 2D cluster had no effect on the ability of 
PQ to eradicate blood stage asexual and sexual parasites 
[30]. The PQ-5,6-orthoquinone or other PQ-hydrox-
ylated metabolites were not detectable in the plasma of 
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Fig. 1 Putative pathway for primaquine metabolism to the PQ‑5,6‑orthoquinone
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KO mice after oral administration of PQ [19]. This sug-
gests either two different mechanisms for PQ liver- and 
blood-stage activities, or that the putative active/haemo-
toxic metabolites  related to PQ-5,6-orthoquinone, were 
formed in the erythrocytes independently of CYP2D6. 
Previous in vitro studies have suggested the possibility of 
formation of PQ haemotoxic metabolites in erythrocytes 
[12, 13].
If active/haemotoxic metabolites of PQ are gener-
ated in the red blood cells (RBCs), it may lead to a better 
understanding of the mechanism of activity and toxicity 
of PQ, and may enable the design of new 8-aminoquino-
lines with safer clinical utility. Therefore, the aim of the 
current study was to evaluate PQ metabolism in human 
RBCs in  vitro, using a stable isotope labelling/tracking 
method for identification of metabolites, as described 
previously in detail [31] and to determine kinetics of for-
mation of PQ-5,6-orthoquinone.
Methods
Materials
13C-labelled PQ (13C-PQ, with 6 isotopic carbons in the 
quinoline nucleus), and PQ-5,6-orthoquinone were syn-
thesized as previously reported [23, 32]. HPLC-grade 
acetonitrile and methanol were purchased from Fisher 
Scientific (Fair Lawn, NJ, USA). Water for the HPLC 
mobile phase was purified in a Milli-Q system (Millipore, 
Bedford, MA, USA). Human haemoglobin (lyophilized 
powder), formic acid and glucose were purchased from 
Sigma-Aldrich (St Louis, MO, USA).
Preparation of RBC for incubation
Fresh human blood from one single normal (non-
G6PD deficient) adult subject was collected into a BD 
 Vacutainer® tube pretreated with EDTA (K2) and refrig-
erated (4 °C) until ready to use, but not longer than 72 h. 
Plasma and leukocyte coat were separated and removed 
after the sample was centrifuged (3000  rpm, 10  min). 
The erythrocytes were washed in three cycles with NaCl 
(0.9%). Each cycle of washing involved the vortexing with 
2 parts saline, centrifugation (3000 rpm, 10 min) and the 
removal of the supernatants.
Incubation of primaquine in erythrocytes/isolated 
haemoglobin
Racemic PQ and the individual enantiomers (S-(+)- and 
R-(−)-primaquine) were incubated separately. For each 
enantiomer, a 50:50 mix of 12C-PQ and 13C-PQ with 6 
13C incorporation (5 µM) was incubated in 20% haemato-
crit (erythrocytes diluted with phosphate-buffered saline 
containing 0.18  M glucose) in a clear 24-well plate at 
37 °C under a humidified atmosphere of 95% air and 5% 
CO2 in an Eppendorf incubator (Hauppauge, NY, USA) 
attached to a shaker set at 75  rpm. Duplicate samples 
were monitored for each and all time points. PQ enan-
tiomers were similarly incubated with isolated haemo-
globin. Control incubations were performed in the buffer 
solution without RBCs or haemoglobin.
Post‑incubation analysis
Two different post-incubation treatments were per-
formed on the incubated RBC samples. For the first 
method (whole RBC treatment), the incubated mixture 
was precipitated with ice-cold methanol intended to halt 
metabolic reactions, lyse the erythrocytes and precipi-
tate the erythrocytic proteins. The resulting samples were 
analysed using UPLC–MS. The second method involved 
the centrifugation of the incubation mixture (without 
adding methanol), separating the samples into pellets 
and supernatants, which were separately analysed. This 
allowed for much better recovery of protein-bound ana-
lytes. The haemoglobin incubations were precipitated 
with ice-cold methanol prior to centrifugation and the 
analysis of the supernatants. In preparing for UPLC–MS 
analysis, samples were diluted with 80% methanol, centri-
fuged (10,000g, 10 min) and the clear supernatants were 
collected and dried using a  Speedvac®. The dried samples 
were re-suspended in 150 µL methanol and centrifuged; 
clear supernatants were transferred to UPLC sample vials 
for analysis.
UPLC/MS metabolite identification
A liquid chromatography-mass spectrometry (LC-MS) 
method for simultaneous analysis of PQ and its metab-
olites was developed and employed in this study. The 
separation of analytes was achieved within a 25-min run 
time on a Waters ACQUITY UPLC™ BEH Shield RP18 
column (100 mm × 2.1 mm I.D., 1.7 µm) equipped with 
an LC-18 guard column (Vanguard 2.1 × 5  mm, Waters 
Corp, Milford, MA, USA) using an ACQUITY UPLC 
system (Waters Corp, Milford, MA, USA). The UPLC 
system includes binary solvent manager, sampler man-
ager, column compartment, and photodiode array (PDA) 
detector. The mobile phase, consisting of water with 
0.05% formic acid (A) and acetonitrile with 0.05% formic 
acid (B), was applied at a flow rate of 0.3 mL/min in the 
following gradient elution: 0–5 min, 1% B; 5–14 min, 1% 
B to 13% B; 14–18 min, 13% B to 25% B; 18–22 min, 25% 
B to 33% B; 22–23 min, 33% B to 43% B; and, 23–25 min, 
43% B to 100% B. Each run was followed by a 3-min wash 
with 100% B and an equilibration period of 3.5 min with 
99% A/1% B. Column and sample temperatures were set 
at 50 and 15 °C, respectively. Injection volume was 10 µL, 
and the strong needle wash (90/10; acetonitrile/water, 
v/v) and weak needle wash solution (10/90; acetonitrile/
water) were used. Peaks were assigned with respect to the 
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mass spectra and retention time of reference compounds 
or tentatively identified on the basis of high resolution 
accurate mass.
Mass spectrometric analyses were performed using 
electrospray ionization (ESI) in positive mode on a 
Waters Xevo G2-S QToF mass spectrometer (Waters 
Corp, Manchester, UK). The MS instrument was oper-
ated in the following conditions: mass scan range of 
50–1200 Da, capillary of 3.0 kV, cone of 30 V, source tem-
perature of 80 °C, desolvation temperature of 450 °C, des-
olvation gas flow of 800 L/h, cone gas flow of 50 L/h, and 
a collision energy of 6 eV. Leucine-enkephalin was used 
for the lock mass at a concentration of 5 ng/mL and flow 
rate of 10 µL/min. Ions [M + H]+ (m/z 556.2771 Da) and 
fragment ion (m/z 278.1141  Da) of leucine-enkephalin 
were applied to ensure mass accuracy during the MS 
analysis. The lock spray interval was set at 30 s, and the 
data were averaged over three scans. The mass spec-
trometer was programmed to step between low (10  V) 
and elevated (10–45 V) collision energies on the gas cell, 
using a scan time of 0.5 s per function.
Metabolites in the accurate mass data were found using 
the  MetaboLynx® software. The data were searched using 
predicted metabolite mass, mass defects, isotope, and 
fragmentation patterns. Particularly helpful was scan-
ning for the isotope (+6 mu) peaks resultant from the 
use of a mixture of equal quantities of 12C and 13C PQ. 
Each sample was subjected to data acquisition in full scan 
and data-dependent positive MS/MS, targeted MS/MS 
(ESI positive ionization mode) and high-resolution MS 
(HRMS) modes using the Waters ACQUITYTM XEVO 
QTOF Mass Spectrometer (Waters Corp, Manchester, 
UK) connected to the UPLC system via an ESI inter-
face. Identification of metabolites was assisted by their 
HRMS data, which were used to calculate their elemen-
tal compositions. The full scan mass data were screened 
and filtered using Waters MetaboLynx XS software. The 
qualitative metabolite identification was performed using 
this software package.
Quantitative analysis of PQ and PQ‑5,6‑orthoquinone
Reference standards of PQ and PQ-5,6-orthoquinone were 
dissolved in water and methanol, respectively. Cell-free 
media, made of phosphate buffered saline, was spiked with 
PQ and PQ-5,6-orthoquinone solutions in triplicate to final 
concentrations between 0.5 and 10 µg/mL (using 6 concen-
tration points). The spiked solutions were treated similarly 
as the incubation mixtures and were analysed with UPLC/
MS. A calibration curve was generated with a linear equa-
tion  (R2 > 0.9), and was used to determine the concentra-
tions of PQ and PQ-5,6-orthoquinone in the incubation 
mixtures. Qualitative detection of PQ-5,6-orthoquinone 
in haemoglobin incubations was done by comparison of 
LC-MS/MS profile with synthetic PQ-5,6-orthoquinone.
Results
A substantial amount of PQ-orthoquinone was detected 
in the RBC incubates of racemic PQ and the individual 
enantiomers, with a rapid disappearance of PQ within the 
first hour. PQ orthoquinone was detected in haemoglobin 
incubation after 30 min with no further observable time-
dependent changes. The metabolites were tracked by fol-
lowing the detection of paired fragments (+6 mu apart). 
The identity of the PQ-orthoquinone was confirmed on 
the basis of predicted mass, observed retention time and 
comparison with synthetic standard (Fig. 2). Both enan-
tiomers of PQ readily gave rise to the PQ-orthoquinone, 
and no significant difference was observed.
In the erythrocyte incubations (with PBS, pH 7.4), the 
majority of the PQ is rapidly partitioned into the red cell 
fraction, with much reduced concentrations in the medium. 
The majority of the conversion of PQ to PQ-orthoquinone 
is observed already at 1 h (with up to 50% substrate deple-
tion) in the red cell fraction, and further incubation for up to 
24 h showed only a slow further PQ depletion (Fig. 3).
More than 75% of the depleted PQ was converted to 
PQ-orthoquinone (Fig.  4). The appearance of the PQ-
orthoquinone tracks closely the disappearance of the par-
ent drug. Small amounts of other metabolites could be 
Fig. 2 LC/MS chromatogram showing orthoquinone and PQ after incubation of human RBCs with PQ containing a mixture of 12C‑PQ and 13C‑PQ 
(13C at 6 quinoline core carbons). The peak at retention time 4.65 min corresponds to the orthoquinone standard, while the peak at 14 min 
corresponds to PQ. The mass spectrometric fragmentation at right shows the expected +6 mu
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observed, but these could not be unequivocally identified 
or quantified.
The recovery of the metabolites from the precipi-
tated and lysed RBCs confirms that these reactions are 
intracellular, although it appears that a fraction of the 
PQ-orthoquinone does appear in the medium. Control 
incubations using buffer alone (without adding RBC or 
haemoglobin) run under similar incubation conditions 
did not yield any metabolites.
Discussion
A majority of the primary metabolites generated by PQ 
in human and animal species are viewed as deriving from 
three distinct pathways: first, the oxidative deamination 
of the side chain mediated by the sequential activity of 
mono-amine oxidase and aldehyde dehydrogenase gener-
ates carboxyprimaquine as a principal metabolite [33–36]; 
second, hydroxylated metabolites formed by ring oxida-
tion, especially through the activity of CYP2D6 [19, 28, 
29]; and thirdly, direct conjugation with glucuronide, glu-
cose, carbamate or acetate [37]. Unlike most other cells, 
mature erythrocytes are anucleated, lacking ribosomes 
and mitochondria, and are thus incapable of protein syn-
thesis. RBCs are equipped with robust metabolic systems 
to maintain cellular energy supply, and enzymes for the 
protection of its vital components from harmful oxidative 
reactions, but are not known to contain substantial activi-
ties analogous to the drug metabolizing CYPs [22, 38].
However, several studies have shown that RBCs may 
contribute to the metabolism of endogenous and exog-
enous substances including drugs [38, 39]. While RBCs 
lack the capacity for conjugation reactions like glucuro-
nidation and sulfation, RBCs’ capability for other conju-
gation reactions, including acetylation, methylation and 
glutathione addition, has been reported [39, 40]. Enzy-
matic oxidation of drugs has not been reported in eryth-
rocytes. However, bioreduction of some compounds has 
been reported [41, 42].
This study unequivocally identifies, for the first time, 
the capacity of erythrocytes to transform PQ to PQ-
5,6-orthoquinone and it accounted for more than 75% of 
depleted PQ. It appears that the initial hydroxylation of 
the quinoline ring of PQ in RBCs may well be caused by 
non-enzymatic radical reactions. Apparent continuation 
of biotransformation even after addition of methanol into 
incubation mixtures, and the observed equal rates and 
amounts of PQ-orthoquinone formation for both PQ (S)- 
and (R)-enantiomers (indicating non-stereospecific nature 
of the biotransformation), support the argument that the 
initial hydroxylation was not enzymatic but radical (Fig. 1). 
In previous studies with CYP 2D6 enzyme, different ring-
hydroxylation profiles for PQ enantiomers was reported, 
and additionally, the rate of formation of PQ-orthoqui-
none for (S)-PQ was roughly twice that for (R)-PQ [29]. 
This enzyme-dependent and preferential PQ oxidation of 
the enantiomers was not observed in the current study.
Oxyhaemoglobin undergoes spontaneous autoxidation 
yielding superoxide radicals and methaemoglobin [22, 
38]. Superoxide dismutase in RBCs converts superoxide 
radicals to hydrogen peroxide, which reacts with fer-
rous ions to form highly reactive hydroxyl radicals. Even 
though a bulk of these ROS is neutralized by oxidative 
defence mechanisms, they tend to oxidize compounds 
such as unsaturated fatty acids in erythrocytes [43].
Hydroxyl radicals are also known to hydroxylate qui-
nolines [44, 45] and other aromatic compounds [46–48] 
even under physiological conditions [47, 49–51]. PQ, an 
Fig. 3 The concentration‑time profiles of primaquine incubated with 
human RBC. Whole RBC treatment involved the precipitation and 
lysing of the cells followed by recovery of the analytes. Alternatively, 
the incubation mixture was separated into the cellular pellets and the 
supernatants prior to analyte recovery and analysis
Fig. 4 The concentration‑time profile of primaquine 
5,6‑orthoquinone formed from primaquine incubation in human 
RBC. Whole RBC treatment involved the precipitation and lysing 
of the cells followed by recovery of the analytes. Alternatively, the 
incubation mixture was separated into the cellular pellets and the 
supernatants prior to analyte recovery and analysis
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8-aminoquinoline with several structural points suscep-
tible to oxidation, especially at the 5-position [52], may 
undergo hydroxylation in the intra-erythrocytic envi-
ronment. The rate of hydroxylation of the quinoline ring 
would depend on the ROS concentration in RBCs. Even 
though ROS concentration in normal RBCs is low, para-
sitized [20, 53] and G6PD-deficient [21] RBCs are known 
to contain elevated levels of ROS. Due to the lack of other 
degradative enzymes, such as MAO in RBCs, accumu-
lated PQ may persist and be susceptible to undergo slow 
quinoline ring hydroxylation the 5-position [52]. It has 
been shown that 5-hydroxyPQ is highly unstable under 
neutral conditions and spontaneously undergoes oxida-
tion to form the quinone-imine, with further breakdown 
to 6-demethyl-5-hydroxy-PQ and PQ-orthoquinone [19]. 
These latter, and perhaps also quinone-imine/5-hydroxy-
PQ, can undergo redox-cycling, generating ROS. This 
process will accelerate the accumulation of ROS espe-
cially in parasitized and G6PD-deficient RBCs [20, 22, 
53]. ROS will kill plasmodial parasites which are known 
to be highly sensitive to externally generated ROS [20, 
21, 53]. Even though the elevated level of drug-induced 
ROS can be neutralized by the oxidative defence mecha-
nism in normal RBCs, the weakened oxidative defence 
mechanism of G6PD-deficient erythrocytes may be over-
whelmed, triggering methaemoglobinaemia, erythrocyte 
damage and subsequent spleenic removal resulting in 
clinical anaemia [22].
It has been suggested that the reactive metabolites of 
PQ are generated in the liver and transported to the RBCs 
prior to clinical manifestation of haemolytic toxicity. PQ-
induced methaemoglobinaemia and haemolysis occur at 
least 24 h after the drug administration [2]. PQ PK stud-
ies in mice [19], have suggested that PQ-5,6-orthoquinone 
is formed extremely rapidly in the liver, and disappeared 
from the circulation very rapidly. In a single-dose PQ PK 
studies in humans, PQ-5,6-orthoquinone was not detect-
able in plasma [36]. The results of this study support an 
alternative explanation that formation of the redox active 
PQ metabolites in RBCs followed by progressive oxidative 
stress may be responsible for PQ-induced haemolysis.
The formation of the PQ-5,6-orthoquinone as a major 
metabolite in RBCs is particularly revealing because of its 
strongly suspected link to the haemolytic response as well 
as blood-stage antiparasitic activity. This may also explain 
the observation that the CYP2D cluster was not required 
for PQ to eradicate the blood-stage asexual and sexual (P. 
berghei) parasites in mice [30]. These results will enhance 
an understanding of PQ metabolism and the contribution 
of RBC in this regard. It will also improve appreciation of 
how PQ can cause haemolysis without the contribution 
of liver metabolism. This understanding may enable the 
design of drug candidates with better therapeutic index.
Conclusion
This study presents new evidence to show that oxidative 
metabolites of PQ can be formed in erythrocytes. The 
major erythrocytic metabolite identified in this study, 
PQ-5,6-orthoquinone, has been suggested to reflect the 
oxidative pathway responsible for blood-stage antipara-
sitic activity and haematotoxicity of primaquine. Fur-
ther studies involving human subjects should include 
analysis of red blood cells, in addition to plasma and 
urine, for relevant metabolites.
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